MAP
JAZZ icon

Moody Aldrich Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Moody Aldrich Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,755
Closed -$211K – 219
2024
Q1 		$211K Buy
1,755
+60
+4% +$7.35K 0.04% 208
2023
Q4 		$208K Sell
1,695
-254
-13% -$31.7K 0.04% 190
2023
Q3 		$252K Buy
+1,949
New +$260K 0.05% 173

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Moody Aldrich Partners's JAZZ Position: Q2 2024 in Review

Moody Aldrich Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2024, closing a stake of 1,755 shares — an estimated $211K sold.

Moody Aldrich Partners first reported a position in JAZZ in Q3 2023 and held it in 3 quarters. The position peaked at $252K in Q3 2023. 455 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

  • Moody Aldrich Partners reported no remaining Jazz Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Moody Aldrich Partners sold 1,755 Jazz Pharmaceuticals shares in Q2 2024, an estimated $211K.
  • Moody Aldrich Partners first reported a position in Jazz Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Moody Aldrich Partners's Jazz Pharmaceuticals position peaked at $252K in Q3 2023.
  • 455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on Moody Aldrich Partners's 13F filing for Q2 2024, filed 24 Jul 2024.